UroTrials

Gemeinsam neue
Wege gehen -
Studienübersicht

Nahaufnahme Mikroskop

Im Folgenden finden Sie eine Übersicht der aktuell in Deutschland laufenden urologischen Studien sowie eine Übersicht der jeweils teilnehmenden Zentren.

ARASTEP

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP; NCT05794906)

Delay Castration

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC (PSMA-DC) – Delay Castration (CAAA617D12302)

EvoPAR-PR01

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01; NCT06120491)

MoonRISe-1

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1; NCT06319820)

OMAHA-3

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer(mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-3;NCT06136624)

OMAHA-4

A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent in Metastatic Castration-resistant Prostate Cancer Post One NHA (OMAHA-4; NCT06136650)

Renal impairment

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function – Renal impairment (CAAA617A12202)

SunRISe-5

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5; NCT06211764)

VOLGA

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA; NCT04960709)

Teilnehmende Zentren

Nach oben scrollen